Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 oct. 2016 10h05 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
20 oct. 2016 08h00 HE | Source: Selecta Biosciences Inc

Selecta Biosciences Presented Preclinical Data Applying SVP-Rapamycin in Gene Therapy at Annual Congress of the European Society of Gene and Cell Therapy

Data underscore potential of SVP-Rapamycin to enhance therapeutic benefit of gene therapies by mitigating unwanted humoral (antibody) and cellular immune responses WATERTOWN, Mass., Oct. 20, 2016 ...
18 oct. 2016 08h00 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10

PHILADELPHIA and OXFORD, United Kingdom, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
12 oct. 2016 09h15 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer

PHILADELPHIA and OXFORD, United Kingdom, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that its amended...
19 sept. 2016 07h30 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization

PHILADELPHIA and OXFORD, United Kingdom, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
08 sept. 2016 08h00 HE | Source: VCANBIO USA Co., Ltd.

VCANBIO USA and VCANBIO Center for Translational Biotechnology Launch in the United States

NATICK, Mass., Sept. 08, 2016 (GLOBE NEWSWIRE) -- VCANBIO USA Co. Ltd. (VCANBIO USA) and VCANBIO Center for Translational Biotechnology (VCANBIO CTB) today announced that they will host an opening...
28 juil. 2016 11h25 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

PHILADELPHIA, Pa. and OXFORD, UK, July 28, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European...
20 juin 2016 18h45 HE | Source: Commence Bio

Commence Bio Receives 1st Patent for MSC1: A New Cancer Immunotherapy Platform

SPARKS, MD --(Marketwired - June 20, 2016) - Commence Bio, Inc. (Commence) today announced the issuance of a patent covering the company's STaRT 41™ technology utilized for producing MSC1 cells....
20 juin 2016 09h30 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European...
05 juin 2016 09h05 HE | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting

PHILADELPHIA and OXFORD, United Kingdom, June 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster...

Page précédente